CJC-1295
Long-acting GHRH analog that stimulates sustained GH and IGF-1 secretion via albumin-binding DAC technology
A randomized, placebo-controlled ascending-dose trial in healthy adults demonstrated dose-dependent 2- to 10-fold increases in plasma GH lasting 6+ days and 1.5- to 3-fold increases in IGF-I lasting 9-11 days after a single subcutaneous injection, with an estimated half-life of 5.8-8.1 days. Multiple dosing produced cumulative effects with IGF-I remaining above baseline for up to 28 days. No serious adverse reactions were reported at doses of 30 or 60 mcg/kg. However, long-term safety data are lacking, and human clinical evidence is limited to a small number of early-phase studies. Animal models suggest potential for muscle recovery in glucocorticoid-induced myopathy when combined with ipamorelin, but this has not been validated in human trials. The compound is detected in anti-doping controls and is prohibited in competitive sports.